Health-care costs of losartan and candesartan in the primary treatment of hypertension

A recent study of two widely used angiotensin receptor blockers reported a reduced risk of cardiovascular events (−14.4%) when using candesartan compared with losartan in the primary treatment of hypertension. In addition to clinical benefits, costs associated with treatment strategies must be consi...

Descripción completa

Detalles Bibliográficos
Autores principales: Henriksson, M, Russell, D, Bodegard, J, Kjeldsen, S, Hasvold, P, Stålhammar, J, Levin, L-Å
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023072/
https://www.ncbi.nlm.nih.gov/pubmed/20376078
http://dx.doi.org/10.1038/jhh.2010.36

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023072/
https://www.ncbi.nlm.nih.gov/pubmed/20376078
http://dx.doi.org/10.1038/jhh.2010.36

Ejemplares similares